Freya Biosciences

About Freya Biosciences

Freya Biosciences is a clinical-stage immunology company developing therapies treating inflammation and immune dysregulation in conditions that affect women. Freya is advancing a diversified pipeline, including two first-in-class Phase 2-ready assets for IVF-related embryo implantation failure and preterm birth. Freya’s science is powered by its DyscoverTM platform, a unique multi-omics data science platform built on a biobank of 1,000+ clinical samples derived from both observational and randomized, placebo controlled trials. This provides deep insights into disease pathway associated markers, allowing for de-risked target identification and patient stratification. Backed by a world-class team with a proven track record in biologics drug development, and supported by an international investor base, including Sofinnova Partners, the Gates Foundation, OMX Ventures, EIFO, and Angelini Ventures, Freya is addressing a critical gap in women's health, developing disease-modifying therapies for patients with conditions where current treatments fall short.